Stroke

A study reveals a significant link between iron deficiency anemia and increased ischemic stroke risk in young adults, highlighting urgent screening needs.

Simple choices like improving diet and increasing exercise can influence a healthy individual’s risk of developing cardiovascular disease.

Our Q1 2025 recap for cardiology spotlights 6 regulatory updates, 5 key trial announcements, and top expert perspectives in cardiac care.

FARES-II trial shows 4-factor PCC is safer, reduces bleeding, transfusions, and complications vs frozen plasma in cardiac surgery.

Data from the REVERSE-IT trial provide vital insight into the efficacy and safety of bentracimab as an FDA decision looms on the horizon.

OAC-naive patients experienced a significantly smaller increase in stroke or systemic embolism with asundexian than apixaban.

The regulatory agency granted 510(k) clearance to Caristo Diagnostics' image analysis software to aid in coronary artery disease diagnosis.

Our top 5 headlines include 5 key FDA decisions, including the first approval for stroke in 3 decades, an expanded indication for pediatric anaphylaxis, and more!

Marking the first stroke medicine approved in nearly 30 years, the single five-second intravenous bolus provides faster administration than the standard of care.

Children who have had a stroke, especially in late primary school, face a greater r risk of anxiety, a study found.

A study found propranolol significantly lowers ischemic stroke risk in women with migraine, highlighting its potential for stroke prevention in high-risk groups.

Siddharth Patel, MD, MPH, discusses how an AZALEA-TIMI 71 analysis presented at ESC Congress 2024.

Asundexian failed to prove noninferiority to apixaban for its primary efficacy outcome in the phase 3 OCEANIC-AF trial.

HIIT exercise post-stroke improved aerobic fitness more than MICT, with significant gains in peak VO2 after 12 weeks.

In a recent UK study, more than half of stroke survivors developed depression within 18 years.

Our February 2024 cardiology month in review, recaps FDA news, top data from International Stroke Conference and major journals, and perspectives form a bevy of key opinion leaders in the field on hot topics and news from across the spectrum of cardiovascular medicine.

Anticoagulation and antiplatelet therapy show no significant difference in recurrent stroke risk among patients with cryptogenic stroke and evidence of atrial cardiopathy.

Blood thinners added to clot-busting medication did not improve 90-day stroke outcomes, leading to early discontinuation of the MOST trial.

Although a new study found antidepressants from SSRI or SNRI did not increase the risk of hemorrhagic stroke or other serious bleeding in ischemic stroke survivors, the risk increased when taking antidepressants of other classes and anti-platelet medications.

Study presented at ISC 2024 suggests Black women with hypertension before age 35 face a 3-fold increase in risk of stroke while hypertension before 45 linked to doubling in stroke risk.

Moderate-to-severe anemia decreased the likelihood of a favorable outcome after mechanical thrombectomy compared with no anemia.

Results of ARIES-HM3 demonstrate use of aspirin was associated with an increased rate of major bleeding following HeartMate 3 implantation.

Anthos Therapeutics halts their phase 2 AZALEA-TIMI 71 trial due to significant reduction in bleeding events with abelacimab, making it a potential breakthrough in anticoagulation therapy for atrial fibrillation.

A secondary analysis of ASPREE is bringing the role of aspirin in primary prevention settings further into question, suggesting daily use of low-dose aspirin was associated with a 38% increase in intracranial bleeding in older adults.

Physical activity concentrated within a 1- to 2-day span was associated with a similarly lower risk of cardiovascular outcomes to more evenly distributed activity.